Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies

10Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The systemic delivery of therapeutic viruses, such as oncolytic viruses or vaccines, is limited by the generation of neutralizing antibodies. While pseudotyping of rhabdoviruses with the lymphocytic choriomeningitis virus glycoprotein has previously allowed for multiple rounds of delivery in mice, this strategy has not translated to other animal models. For the first time, we provide experimental evidence that antibodies generated against the lymphocytic choriomeningitis virus glycoprotein mediate robust complement-dependent viral neutralization via activation of the classical pathway. We show that this phenotype can be capitalized upon to deliver maraba virus pseudotyped with the lymphocytic choriomeningitis virus glycoprotein in a Fischer rat model in the face of neutralizing antibody through the use of complement modulators. This finding changes the understanding of the humoral immune response to arenaviruses, and also describes methodology to deliver viral vectors to their therapeutic sites of action without the interference of neutralizing antibody.

References Powered by Scopus

Complement: A key system for immune surveillance and homeostasis

2896Citations
N/AReaders
Get full text

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

718Citations
N/AReaders
Get full text

Antiviral antibody responses: The two extremes of a wide spectrum

257Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Complementing the cancer-immunity cycle

148Citations
N/AReaders
Get full text

Immune system, friend or foe of oncolytic virotherapy?

104Citations
N/AReaders
Get full text

Ecent advances in vesicular stomatitis virus-based oncolytic virotherapy: A 5-year update

79Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Evgin, L., Ilkow, C. S., Bourgeois-Daigneault, M. C., De Souza, C. T., Stubbert, L., Huh, M. S., … Bell, J. C. (2016). Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular Therapy Oncolytics, 3, 16027. https://doi.org/10.1038/mto.2016.27

Readers over time

‘17‘18‘19‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

60%

Researcher 6

30%

Professor / Associate Prof. 2

10%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 7

37%

Medicine and Dentistry 6

32%

Immunology and Microbiology 4

21%

Pharmacology, Toxicology and Pharmaceut... 2

11%

Save time finding and organizing research with Mendeley

Sign up for free
0